This is a news story, published by Yahoo Finance, that relates primarily to Biohaven news.
For more Biohaven news, you can click here:
more Biohaven newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
brainer healthcare stocks. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest low valuation news, cheap share prices news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
low share priceThe Motley Fool
•79% Informative
We asked Three Motley Fool contributors to name no-brainer healthcare stocks to buy for under $100 right now.
AstraZeneca is a growth beast with loads of potential upside.
Pfizer faces a looming patent cliff, while Bristol Myers Squibb faces a sinking brick wall.
Pfizer thinks new products and indications will add around $20 billion to its annual sales by 2030 .
Pfizer built a massive cash stockpile when its COVID-19 vaccine sales were booming.
The company acquired Arena , Biohaven , and Reviral in 2022 , and bought Seagen last year .
Management is looking for around $25 billion in additional revenue by 2030 from its business development deals.
VR Score
75
Informative language
71
Neutral language
45
Article tone
semi-formal
Language
English
Language complexity
40
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
9
Source diversity
2
Affiliate links
no affiliate links